[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$frbnZCfICmv5MygC3jUGEXno2JLkVwJsE_oyyE9_uuOk":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":32,"phaseBuckets":83,"rows":90},"Medical University of Gdansk",[4],123,false,39,4,125884,15,86,[14,17,19,21,23,26,28,30],{"name":15,"count":16},"Chronic Kidney Disease",5,{"name":18,"count":16},"Proteinuria",{"name":20,"count":9},"Healthy",{"name":22,"count":9},"Acute Kidney Injury",{"name":24,"count":25},"Major Depressive Disorder",3,{"name":27,"count":25},"Colorectal Cancer",{"name":29,"count":25},"Manual Therapy",{"name":31,"count":25},"Manipulation",[33,38,43,48,53,58,63,68,73,78],{"nctId":34,"briefTitle":35,"date":36,"intervention":37},"NCT04866654","Radiation Free Chemotherapy for Early Hodgkin Lymphoma","2022-09-30","Nivolumab 10 MG\u002FML",{"nctId":39,"briefTitle":40,"date":41,"intervention":42},"NCT05066633","The Efficacy and Safety of Metoprolol as add-on Treatment to Standard of Care in Preventing Cardiomyopathy in Patients With DMD","2023-06-30","Metoprolol Succinate",{"nctId":44,"briefTitle":45,"date":46,"intervention":47},"NCT06011460","Observation of Clozapine Treatment Safety in Bipolar Disorder.","2024-12-31","Clozapine",{"nctId":49,"briefTitle":50,"date":51,"intervention":52},"NCT05067530","Cyclin dEpendent Kinase in tRiple nEGatIVe brEast canceR - a \"Window of Opportunity\" Study","2025-01-01","Palbociclib",{"nctId":54,"briefTitle":55,"date":56,"intervention":57},"NCT06759623","Assessment of Pulmonary Function in Relation to the Anesthetic Used in Patients Undergoing Bariatric Surgery","2026-04-01","Different drug type for conduction of general anesthesia",{"nctId":59,"briefTitle":60,"date":61,"intervention":62},"NCT07270263","Reduced-Dose Apixaban and Rivaroxaban Versus Low-Molecular-Weight Heparin in Patients With Hematologic Malignancies","2026-04-30","Apixaban",{"nctId":64,"briefTitle":65,"date":66,"intervention":67},"NCT06571344","Vitamin D in Dialysis Patients - Diagnostic and Therapeutic Management","2026-12-31","Cholecalciferol",{"nctId":69,"briefTitle":70,"date":71,"intervention":72},"NCT06917963","Study of Treatment With Intensified Omeprazole Treatment to Prevent High Output Stoma 1","2027-06","Intensified intravenous omeprazole therapy",{"nctId":74,"briefTitle":75,"date":76,"intervention":77},"NCT07277881","The Effect of Reversal of Remimazolam Sedation With Flumazenil on Cognitive Function in Patients Undergoing Hip Arthroplasty Under Spinal Anesthesia","2027-10","remimazolam sedation reversal with flumazenil",{"nctId":79,"briefTitle":80,"date":81,"intervention":82},"NCT05565352","Ketamine Safety and Tolerability in Psychiatric Inpatient Care (KetGD)","2029-12-31","Ketamine Hydrochloride",[84,85,86,87,88,89],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[91,119,141,163,187,205,223,243,269,298,316,334,356,376,404,422,448,474,501,519,544,571,589,615,643,661,693,711,729,747,774,792,810,835,853,879,897,922,946,987,1014,1032,1059,1084,1102,1124,1150,1176,1201,1219,1243,1270,1294,1316,1334],{"intervention":77,"totalTrials":92,"cells":93},1,{"EARLY_PHASE1":94,"PHASE1":97,"PHASE2":99,"PHASE3":101,"PHASE4":103,"NA":117},{"trials":95,"activeCount":96},[],0,{"trials":98,"activeCount":96},[],{"trials":100,"activeCount":96},[],{"trials":102,"activeCount":96},[],{"trials":104,"activeCount":92,"soonestReadout":76},[105],{"nctId":74,"briefTitle":75,"status":106,"phases":107,"primaryCompletion":76,"completion":108,"start":109,"enrollment":110,"conditions":111,"interventions":116},"NOT_YET_RECRUITING",[88],"2028-10","2026-01",150,[112,113,114,115],"Postoperative Delirium","Sedation","Remimazolam","Hip Arthroplasty, Total",[77],{"trials":118,"activeCount":96},[],{"intervention":42,"totalTrials":92,"cells":120},{"EARLY_PHASE1":121,"PHASE1":123,"PHASE2":125,"PHASE3":127,"PHASE4":137,"NA":139},{"trials":122,"activeCount":96},[],{"trials":124,"activeCount":96},[],{"trials":126,"activeCount":96},[],{"trials":128,"activeCount":92,"soonestReadout":41},[129],{"nctId":39,"briefTitle":40,"status":130,"phases":131,"primaryCompletion":41,"completion":132,"start":133,"enrollment":110,"conditions":134,"interventions":136},"RECRUITING",[87],"2026-06-30","2021-08-18",[135],"Muscular Dystrophy, Duchenne",[42],{"trials":138,"activeCount":96},[],{"trials":140,"activeCount":96},[],{"intervention":37,"totalTrials":92,"cells":142},{"EARLY_PHASE1":143,"PHASE1":145,"PHASE2":147,"PHASE3":157,"PHASE4":159,"NA":161},{"trials":144,"activeCount":96},[],{"trials":146,"activeCount":96},[],{"trials":148,"activeCount":92,"soonestReadout":36},[149],{"nctId":34,"briefTitle":35,"status":130,"phases":150,"primaryCompletion":36,"completion":151,"start":152,"enrollment":153,"conditions":154,"interventions":156},[86],"2026-07-02","2021-03-04",160,[155],"Hodgkin Lymphoma",[37],{"trials":158,"activeCount":96},[],{"trials":160,"activeCount":96},[],{"trials":162,"activeCount":96},[],{"intervention":52,"totalTrials":92,"cells":164},{"EARLY_PHASE1":165,"PHASE1":167,"PHASE2":169,"PHASE3":181,"PHASE4":183,"NA":185},{"trials":166,"activeCount":96},[],{"trials":168,"activeCount":96},[],{"trials":170,"activeCount":92,"soonestReadout":51},[171],{"nctId":49,"briefTitle":50,"status":106,"phases":172,"primaryCompletion":51,"completion":173,"start":174,"enrollment":175,"conditions":176,"interventions":178},[86],"2026-12-06","2022-01-01",126,[177],"Triple Negative Breast Neoplasms",[52,179,180],"Paclitaxel","Carboplatin",{"trials":182,"activeCount":96},[],{"trials":184,"activeCount":96},[],{"trials":186,"activeCount":96},[],{"intervention":179,"totalTrials":92,"cells":188},{"EARLY_PHASE1":189,"PHASE1":191,"PHASE2":193,"PHASE3":199,"PHASE4":201,"NA":203},{"trials":190,"activeCount":96},[],{"trials":192,"activeCount":96},[],{"trials":194,"activeCount":92,"soonestReadout":51},[195],{"nctId":49,"briefTitle":50,"status":106,"phases":196,"primaryCompletion":51,"completion":173,"start":174,"enrollment":175,"conditions":197,"interventions":198},[86],[177],[52,179,180],{"trials":200,"activeCount":96},[],{"trials":202,"activeCount":96},[],{"trials":204,"activeCount":96},[],{"intervention":180,"totalTrials":92,"cells":206},{"EARLY_PHASE1":207,"PHASE1":209,"PHASE2":211,"PHASE3":217,"PHASE4":219,"NA":221},{"trials":208,"activeCount":96},[],{"trials":210,"activeCount":96},[],{"trials":212,"activeCount":92,"soonestReadout":51},[213],{"nctId":49,"briefTitle":50,"status":106,"phases":214,"primaryCompletion":51,"completion":173,"start":174,"enrollment":175,"conditions":215,"interventions":216},[86],[177],[52,179,180],{"trials":218,"activeCount":96},[],{"trials":220,"activeCount":96},[],{"trials":222,"activeCount":96},[],{"intervention":67,"totalTrials":92,"cells":224},{"EARLY_PHASE1":225,"PHASE1":227,"PHASE2":229,"PHASE3":231,"PHASE4":233,"NA":235},{"trials":226,"activeCount":96},[],{"trials":228,"activeCount":96},[],{"trials":230,"activeCount":96},[],{"trials":232,"activeCount":96},[],{"trials":234,"activeCount":96},[],{"trials":236,"activeCount":92,"soonestReadout":66},[237],{"nctId":64,"briefTitle":65,"status":130,"phases":238,"primaryCompletion":66,"completion":66,"start":239,"enrollment":153,"conditions":240,"interventions":242},[],"2022-11-01",[241],"Vitamin D Deficiency Due to Chronic Kidney Disease",[67],{"intervention":82,"totalTrials":92,"cells":244},{"EARLY_PHASE1":245,"PHASE1":247,"PHASE2":249,"PHASE3":251,"PHASE4":253,"NA":255},{"trials":246,"activeCount":96},[],{"trials":248,"activeCount":96},[],{"trials":250,"activeCount":96},[],{"trials":252,"activeCount":96},[],{"trials":254,"activeCount":96},[],{"trials":256,"activeCount":92,"soonestReadout":81},[257],{"nctId":79,"briefTitle":80,"status":258,"phases":259,"primaryCompletion":81,"completion":81,"start":260,"enrollment":261,"conditions":262,"interventions":268},"ENROLLING_BY_INVITATION",[],"2022-09-01",140,[24,263,264,265,266,267],"Post Traumatic Stress Disorder","Obsessive-Compulsive Disorder","Somatoform Disorders","Anxiety Disorders","Dissociative Disorder",[82],{"intervention":62,"totalTrials":92,"cells":270},{"EARLY_PHASE1":271,"PHASE1":273,"PHASE2":275,"PHASE3":277,"PHASE4":279,"NA":281},{"trials":272,"activeCount":96},[],{"trials":274,"activeCount":96},[],{"trials":276,"activeCount":96},[],{"trials":278,"activeCount":96},[],{"trials":280,"activeCount":96},[],{"trials":282,"activeCount":92,"soonestReadout":61},[283],{"nctId":59,"briefTitle":60,"status":130,"phases":284,"primaryCompletion":61,"completion":66,"start":285,"enrollment":286,"conditions":287,"interventions":295},[89],"2024-11-22",100,[288,289,290,291,292,293,294],"Lymphoma","Leukemia","Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma","Venous Thromboembolic Disease","VTE (Venous Thromboembolism)","PE - Pulmonary Embolism","Hematologic Malignacies",[62,296,297],"Rivaroxaban","low molecular weight heparin",{"intervention":296,"totalTrials":92,"cells":299},{"EARLY_PHASE1":300,"PHASE1":302,"PHASE2":304,"PHASE3":306,"PHASE4":308,"NA":310},{"trials":301,"activeCount":96},[],{"trials":303,"activeCount":96},[],{"trials":305,"activeCount":96},[],{"trials":307,"activeCount":96},[],{"trials":309,"activeCount":96},[],{"trials":311,"activeCount":92,"soonestReadout":61},[312],{"nctId":59,"briefTitle":60,"status":130,"phases":313,"primaryCompletion":61,"completion":66,"start":285,"enrollment":286,"conditions":314,"interventions":315},[89],[288,289,290,291,292,293,294],[62,296,297],{"intervention":297,"totalTrials":92,"cells":317},{"EARLY_PHASE1":318,"PHASE1":320,"PHASE2":322,"PHASE3":324,"PHASE4":326,"NA":328},{"trials":319,"activeCount":96},[],{"trials":321,"activeCount":96},[],{"trials":323,"activeCount":96},[],{"trials":325,"activeCount":96},[],{"trials":327,"activeCount":96},[],{"trials":329,"activeCount":92,"soonestReadout":61},[330],{"nctId":59,"briefTitle":60,"status":130,"phases":331,"primaryCompletion":61,"completion":66,"start":285,"enrollment":286,"conditions":332,"interventions":333},[89],[288,289,290,291,292,293,294],[62,296,297],{"intervention":47,"totalTrials":92,"cells":335},{"EARLY_PHASE1":336,"PHASE1":338,"PHASE2":340,"PHASE3":342,"PHASE4":344,"NA":346},{"trials":337,"activeCount":96},[],{"trials":339,"activeCount":96},[],{"trials":341,"activeCount":96},[],{"trials":343,"activeCount":96},[],{"trials":345,"activeCount":96},[],{"trials":347,"activeCount":92,"soonestReadout":46},[348],{"nctId":44,"briefTitle":45,"status":258,"phases":349,"primaryCompletion":46,"completion":350,"start":351,"enrollment":352,"conditions":353,"interventions":355},[],"2027-06-30","2023-02-23",30,[354],"Bipolar Disorder",[47],{"intervention":57,"totalTrials":92,"cells":357},{"EARLY_PHASE1":358,"PHASE1":360,"PHASE2":362,"PHASE3":364,"PHASE4":366,"NA":368},{"trials":359,"activeCount":96},[],{"trials":361,"activeCount":96},[],{"trials":363,"activeCount":96},[],{"trials":365,"activeCount":96},[],{"trials":367,"activeCount":96},[],{"trials":369,"activeCount":92,"soonestReadout":56},[370],{"nctId":54,"briefTitle":55,"status":130,"phases":371,"primaryCompletion":56,"completion":56,"start":372,"enrollment":286,"conditions":373,"interventions":375},[89],"2025-01-08",[374],"Obesity and Obesity-related Medical Conditions",[57],{"intervention":72,"totalTrials":92,"cells":377},{"EARLY_PHASE1":378,"PHASE1":380,"PHASE2":382,"PHASE3":384,"PHASE4":386,"NA":388},{"trials":379,"activeCount":96},[],{"trials":381,"activeCount":96},[],{"trials":383,"activeCount":96},[],{"trials":385,"activeCount":96},[],{"trials":387,"activeCount":96},[],{"trials":389,"activeCount":92,"soonestReadout":71},[390],{"nctId":69,"briefTitle":70,"status":130,"phases":391,"primaryCompletion":71,"completion":392,"start":393,"enrollment":394,"conditions":395,"interventions":402},[89],"2027-07","2025-04-10",80,[396,397,398,399,400,401],"Stoma - Ileostomy","High Output Stoma","Colon Cancer","IBD (Inflammatory Bowel Disease)","Ileus","Omeprazole",[72,403],"Standard intravenous omeprazole therapy (40 mg IV once daily at 6:00 AM).",{"intervention":403,"totalTrials":92,"cells":405},{"EARLY_PHASE1":406,"PHASE1":408,"PHASE2":410,"PHASE3":412,"PHASE4":414,"NA":416},{"trials":407,"activeCount":96},[],{"trials":409,"activeCount":96},[],{"trials":411,"activeCount":96},[],{"trials":413,"activeCount":96},[],{"trials":415,"activeCount":96},[],{"trials":417,"activeCount":92,"soonestReadout":71},[418],{"nctId":69,"briefTitle":70,"status":130,"phases":419,"primaryCompletion":71,"completion":392,"start":393,"enrollment":394,"conditions":420,"interventions":421},[89],[396,397,398,399,400,401],[72,403],{"intervention":423,"totalTrials":92,"cells":424},"Dexmedetomidine",{"EARLY_PHASE1":425,"PHASE1":427,"PHASE2":429,"PHASE3":431,"PHASE4":433,"NA":446},{"trials":426,"activeCount":96},[],{"trials":428,"activeCount":96},[],{"trials":430,"activeCount":96},[],{"trials":432,"activeCount":96},[],{"trials":434,"activeCount":96},[435],{"nctId":436,"briefTitle":437,"status":438,"phases":439,"primaryCompletion":440,"completion":440,"start":441,"enrollment":442,"conditions":443,"interventions":445},"NCT02566863","Haemodynamic Effect of Dexmedetomidine","COMPLETED",[88],"2018-08","2015-06",64,[444],"Haemodynamic Effects of Dexmedetomidine",[423],{"trials":447,"activeCount":96},[],{"intervention":449,"totalTrials":92,"cells":450},"Remifentanil",{"EARLY_PHASE1":451,"PHASE1":453,"PHASE2":455,"PHASE3":457,"PHASE4":459,"NA":472},{"trials":452,"activeCount":96},[],{"trials":454,"activeCount":96},[],{"trials":456,"activeCount":96},[],{"trials":458,"activeCount":96},[],{"trials":460,"activeCount":96},[461],{"nctId":462,"briefTitle":463,"status":438,"phases":464,"primaryCompletion":465,"completion":466,"start":467,"enrollment":468,"conditions":469,"interventions":471},"NCT01714388","Vagotonic Effect of Remifentanil and Autonomic Nervous System Activity.",[88],"2015-02","2015-03","2010-05",70,[470],"Autonomic Nervous System Activity",[449],{"trials":473,"activeCount":96},[],{"intervention":475,"totalTrials":92,"cells":476},"oral metformin",{"EARLY_PHASE1":477,"PHASE1":479,"PHASE2":481,"PHASE3":483,"PHASE4":485,"NA":499},{"trials":478,"activeCount":96},[],{"trials":480,"activeCount":96},[],{"trials":482,"activeCount":96},[],{"trials":484,"activeCount":96},[],{"trials":486,"activeCount":96},[487],{"nctId":488,"briefTitle":489,"status":490,"phases":491,"primaryCompletion":492,"completion":492,"start":493,"enrollment":494,"conditions":495,"interventions":497},"NCT01798875","PCOS, Therapy and Markers of Cardiovascular Risk","UNKNOWN",[88],"2015-12","2012-04",50,[496],"PCOS",[475,498],"oral contraceptive",{"trials":500,"activeCount":96},[],{"intervention":498,"totalTrials":92,"cells":502},{"EARLY_PHASE1":503,"PHASE1":505,"PHASE2":507,"PHASE3":509,"PHASE4":511,"NA":517},{"trials":504,"activeCount":96},[],{"trials":506,"activeCount":96},[],{"trials":508,"activeCount":96},[],{"trials":510,"activeCount":96},[],{"trials":512,"activeCount":96},[513],{"nctId":488,"briefTitle":489,"status":490,"phases":514,"primaryCompletion":492,"completion":492,"start":493,"enrollment":494,"conditions":515,"interventions":516},[88],[496],[475,498],{"trials":518,"activeCount":96},[],{"intervention":520,"totalTrials":92,"cells":521},"aliskiren, eplerenon, telmisartan",{"EARLY_PHASE1":522,"PHASE1":524,"PHASE2":526,"PHASE3":528,"PHASE4":530,"NA":542},{"trials":523,"activeCount":96},[],{"trials":525,"activeCount":96},[],{"trials":527,"activeCount":96},[],{"trials":529,"activeCount":96},[],{"trials":531,"activeCount":96},[532],{"nctId":533,"briefTitle":534,"status":438,"phases":535,"primaryCompletion":536,"completion":537,"start":538,"enrollment":539,"conditions":540,"interventions":541},"NCT01541267","The Effect of Various Types of the Renin-angiotensin-aldosterone System Blockade on Proteinuria",[88],"2011-05","2011-11","2009-12",20,[15,18],[520],{"trials":543,"activeCount":96},[],{"intervention":545,"totalTrials":92,"cells":546},"Diprivan",{"EARLY_PHASE1":547,"PHASE1":549,"PHASE2":551,"PHASE3":553,"PHASE4":555,"NA":569},{"trials":548,"activeCount":96},[],{"trials":550,"activeCount":96},[],{"trials":552,"activeCount":96},[],{"trials":554,"activeCount":96},[],{"trials":556,"activeCount":96},[557],{"nctId":558,"briefTitle":559,"status":560,"phases":561,"primaryCompletion":562,"completion":562,"start":563,"enrollment":96,"conditions":564,"interventions":567},"NCT00541918","COGNITIVE - Cognitive Function After Sevoflurane or Propofol Anesthesia for Open-heart Operations","WITHDRAWN",[88],"2015-04","2007-06",[565,566],"Other Functional Disturbances Following Cardiac Surgery","Memory Disorders",[545,568],"Sevorane",{"trials":570,"activeCount":96},[],{"intervention":568,"totalTrials":92,"cells":572},{"EARLY_PHASE1":573,"PHASE1":575,"PHASE2":577,"PHASE3":579,"PHASE4":581,"NA":587},{"trials":574,"activeCount":96},[],{"trials":576,"activeCount":96},[],{"trials":578,"activeCount":96},[],{"trials":580,"activeCount":96},[],{"trials":582,"activeCount":96},[583],{"nctId":558,"briefTitle":559,"status":560,"phases":584,"primaryCompletion":562,"completion":562,"start":563,"enrollment":96,"conditions":585,"interventions":586},[88],[565,566],[545,568],{"trials":588,"activeCount":96},[],{"intervention":590,"totalTrials":92,"cells":591},"Aliskiren, Perindopril",{"EARLY_PHASE1":592,"PHASE1":594,"PHASE2":596,"PHASE3":598,"PHASE4":600,"NA":613},{"trials":593,"activeCount":96},[],{"trials":595,"activeCount":96},[],{"trials":597,"activeCount":96},[],{"trials":599,"activeCount":96},[],{"trials":601,"activeCount":96},[602],{"nctId":603,"briefTitle":604,"status":438,"phases":605,"primaryCompletion":606,"completion":607,"start":608,"enrollment":609,"conditions":610,"interventions":612},"NCT01219413","Influence of Aliskiren on Proteinuria",[88],"2010-07","2010-09","2009-03",16,[15,18,611],"Blood Pressure",[590],{"trials":614,"activeCount":96},[],{"intervention":616,"totalTrials":92,"cells":617},"Del Nido Cardioplegia Solution",{"EARLY_PHASE1":618,"PHASE1":620,"PHASE2":622,"PHASE3":624,"PHASE4":626,"NA":641},{"trials":619,"activeCount":96},[],{"trials":621,"activeCount":96},[],{"trials":623,"activeCount":96},[],{"trials":625,"activeCount":96},[],{"trials":627,"activeCount":96},[628],{"nctId":629,"briefTitle":630,"status":490,"phases":631,"primaryCompletion":632,"completion":633,"start":634,"enrollment":286,"conditions":635,"interventions":639},"NCT06235424","Del Nido Versus HTK Cardioplegia in Adult Aortic Valve Replacement",[88],"2023-04-24","2024-09-24","2018-10-01",[636,637,638],"Aortic Valve Disease","Valve Disease, Heart","Cardiac Ischemia",[616,640],"HTK solution",{"trials":642,"activeCount":96},[],{"intervention":640,"totalTrials":92,"cells":644},{"EARLY_PHASE1":645,"PHASE1":647,"PHASE2":649,"PHASE3":651,"PHASE4":653,"NA":659},{"trials":646,"activeCount":96},[],{"trials":648,"activeCount":96},[],{"trials":650,"activeCount":96},[],{"trials":652,"activeCount":96},[],{"trials":654,"activeCount":96},[655],{"nctId":629,"briefTitle":630,"status":490,"phases":656,"primaryCompletion":632,"completion":633,"start":634,"enrollment":286,"conditions":657,"interventions":658},[88],[636,637,638],[616,640],{"trials":660,"activeCount":96},[],{"intervention":662,"totalTrials":92,"cells":663},"Ticagrelor",{"EARLY_PHASE1":664,"PHASE1":666,"PHASE2":668,"PHASE3":670,"PHASE4":672,"NA":691},{"trials":665,"activeCount":96},[],{"trials":667,"activeCount":96},[],{"trials":669,"activeCount":96},[],{"trials":671,"activeCount":96},[],{"trials":673,"activeCount":96},[674],{"nctId":675,"briefTitle":676,"status":490,"phases":677,"primaryCompletion":678,"completion":679,"start":680,"enrollment":681,"conditions":682,"interventions":687},"NCT04695106","Dual Antithrombotic Therapy With Dabigatran and Ticagrelor in Patients With ACS and Non-valvular AF Undergoing PCI",[88],"2024-03-01","2026-03-31","2021-10-25",2230,[683,684,685,686],"Atrial Fibrillation","Antithrombotic Therapy","Acute Coronary Syndrome","Percutaneous Coronary Interventions",[662,688,689,690],"Dabigatran Etexilate","Aspirin","Clopidogrel",{"trials":692,"activeCount":96},[],{"intervention":688,"totalTrials":92,"cells":694},{"EARLY_PHASE1":695,"PHASE1":697,"PHASE2":699,"PHASE3":701,"PHASE4":703,"NA":709},{"trials":696,"activeCount":96},[],{"trials":698,"activeCount":96},[],{"trials":700,"activeCount":96},[],{"trials":702,"activeCount":96},[],{"trials":704,"activeCount":96},[705],{"nctId":675,"briefTitle":676,"status":490,"phases":706,"primaryCompletion":678,"completion":679,"start":680,"enrollment":681,"conditions":707,"interventions":708},[88],[683,684,685,686],[662,688,689,690],{"trials":710,"activeCount":96},[],{"intervention":689,"totalTrials":92,"cells":712},{"EARLY_PHASE1":713,"PHASE1":715,"PHASE2":717,"PHASE3":719,"PHASE4":721,"NA":727},{"trials":714,"activeCount":96},[],{"trials":716,"activeCount":96},[],{"trials":718,"activeCount":96},[],{"trials":720,"activeCount":96},[],{"trials":722,"activeCount":96},[723],{"nctId":675,"briefTitle":676,"status":490,"phases":724,"primaryCompletion":678,"completion":679,"start":680,"enrollment":681,"conditions":725,"interventions":726},[88],[683,684,685,686],[662,688,689,690],{"trials":728,"activeCount":96},[],{"intervention":690,"totalTrials":92,"cells":730},{"EARLY_PHASE1":731,"PHASE1":733,"PHASE2":735,"PHASE3":737,"PHASE4":739,"NA":745},{"trials":732,"activeCount":96},[],{"trials":734,"activeCount":96},[],{"trials":736,"activeCount":96},[],{"trials":738,"activeCount":96},[],{"trials":740,"activeCount":96},[741],{"nctId":675,"briefTitle":676,"status":490,"phases":742,"primaryCompletion":678,"completion":679,"start":680,"enrollment":681,"conditions":743,"interventions":744},[88],[683,684,685,686],[662,688,689,690],{"trials":746,"activeCount":96},[],{"intervention":748,"totalTrials":92,"cells":749},"Xomolix 0.625 mg intravenously",{"EARLY_PHASE1":750,"PHASE1":752,"PHASE2":754,"PHASE3":756,"PHASE4":758,"NA":772},{"trials":751,"activeCount":96},[],{"trials":753,"activeCount":96},[],{"trials":755,"activeCount":96},[],{"trials":757,"activeCount":96},[],{"trials":759,"activeCount":96},[760],{"nctId":761,"briefTitle":762,"status":438,"phases":763,"primaryCompletion":764,"completion":764,"start":765,"enrollment":766,"conditions":767,"interventions":769},"NCT01819857","Droperidol and Cardiac Repolarization",[88],"2013-07","2011-06",75,[768],"Cardiac Repolarization",[748,770,771],"Xomolix 1.25 mg","Zofran 8 mg",{"trials":773,"activeCount":96},[],{"intervention":770,"totalTrials":92,"cells":775},{"EARLY_PHASE1":776,"PHASE1":778,"PHASE2":780,"PHASE3":782,"PHASE4":784,"NA":790},{"trials":777,"activeCount":96},[],{"trials":779,"activeCount":96},[],{"trials":781,"activeCount":96},[],{"trials":783,"activeCount":96},[],{"trials":785,"activeCount":96},[786],{"nctId":761,"briefTitle":762,"status":438,"phases":787,"primaryCompletion":764,"completion":764,"start":765,"enrollment":766,"conditions":788,"interventions":789},[88],[768],[748,770,771],{"trials":791,"activeCount":96},[],{"intervention":771,"totalTrials":92,"cells":793},{"EARLY_PHASE1":794,"PHASE1":796,"PHASE2":798,"PHASE3":800,"PHASE4":802,"NA":808},{"trials":795,"activeCount":96},[],{"trials":797,"activeCount":96},[],{"trials":799,"activeCount":96},[],{"trials":801,"activeCount":96},[],{"trials":803,"activeCount":96},[804],{"nctId":761,"briefTitle":762,"status":438,"phases":805,"primaryCompletion":764,"completion":764,"start":765,"enrollment":766,"conditions":806,"interventions":807},[88],[768],[748,770,771],{"trials":809,"activeCount":96},[],{"intervention":811,"totalTrials":92,"cells":812},"Diprivan (propofol), Astra-Zeneca",{"EARLY_PHASE1":813,"PHASE1":815,"PHASE2":817,"PHASE3":819,"PHASE4":821,"NA":833},{"trials":814,"activeCount":96},[],{"trials":816,"activeCount":96},[],{"trials":818,"activeCount":96},[],{"trials":820,"activeCount":96},[],{"trials":822,"activeCount":96},[823],{"nctId":824,"briefTitle":825,"status":438,"phases":826,"primaryCompletion":827,"completion":827,"start":828,"enrollment":394,"conditions":829,"interventions":831},"NCT00528515","Desflurane Versus Propofol Anesthesia for Off-Pump CABG",[88],"2008-03","2007-02",[830],"Coronary Artery Disease",[811,832],"Suprane (desflurane), Baxter",{"trials":834,"activeCount":96},[],{"intervention":832,"totalTrials":92,"cells":836},{"EARLY_PHASE1":837,"PHASE1":839,"PHASE2":841,"PHASE3":843,"PHASE4":845,"NA":851},{"trials":838,"activeCount":96},[],{"trials":840,"activeCount":96},[],{"trials":842,"activeCount":96},[],{"trials":844,"activeCount":96},[],{"trials":846,"activeCount":96},[847],{"nctId":824,"briefTitle":825,"status":438,"phases":848,"primaryCompletion":827,"completion":827,"start":828,"enrollment":394,"conditions":849,"interventions":850},[88],[830],[811,832],{"trials":852,"activeCount":96},[],{"intervention":854,"totalTrials":92,"cells":855},"fenoldopam",{"EARLY_PHASE1":856,"PHASE1":858,"PHASE2":860,"PHASE3":862,"PHASE4":875,"NA":877},{"trials":857,"activeCount":96},[],{"trials":859,"activeCount":96},[],{"trials":861,"activeCount":96},[],{"trials":863,"activeCount":96},[864],{"nctId":865,"briefTitle":866,"status":867,"phases":868,"primaryCompletion":562,"completion":562,"start":869,"enrollment":870,"conditions":871,"interventions":873},"NCT00557219","Fenoldopam and Ketanserin for Acute Kidney Failure Prevention After Cardiac Surgery","TERMINATED",[87],"2008-04",60,[872],"Acute Renal Failure",[854,874],"ketanserin",{"trials":876,"activeCount":96},[],{"trials":878,"activeCount":96},[],{"intervention":874,"totalTrials":92,"cells":880},{"EARLY_PHASE1":881,"PHASE1":883,"PHASE2":885,"PHASE3":887,"PHASE4":893,"NA":895},{"trials":882,"activeCount":96},[],{"trials":884,"activeCount":96},[],{"trials":886,"activeCount":96},[],{"trials":888,"activeCount":96},[889],{"nctId":865,"briefTitle":866,"status":867,"phases":890,"primaryCompletion":562,"completion":562,"start":869,"enrollment":870,"conditions":891,"interventions":892},[87],[872],[854,874],{"trials":894,"activeCount":96},[],{"trials":896,"activeCount":96},[],{"intervention":898,"totalTrials":92,"cells":899},"celecoxib",{"EARLY_PHASE1":900,"PHASE1":902,"PHASE2":904,"PHASE3":906,"PHASE4":918,"NA":920},{"trials":901,"activeCount":96},[],{"trials":903,"activeCount":96},[],{"trials":905,"activeCount":96},[],{"trials":907,"activeCount":96},[908],{"nctId":909,"briefTitle":910,"status":911,"phases":912,"start":913,"enrollment":914,"conditions":915,"interventions":917},"NCT00211952","Adjuvant Celecoxib in Completely Resected pN1-2 NSCLC Patients","SUSPENDED",[87],"2004-03",542,[916],"Non-Small Cell Lung Cancer",[898],{"trials":919,"activeCount":96},[],{"trials":921,"activeCount":96},[],{"intervention":923,"totalTrials":92,"cells":924},"Morphine hydrochloride",{"EARLY_PHASE1":925,"PHASE1":927,"PHASE2":929,"PHASE3":931,"PHASE4":942,"NA":944},{"trials":926,"activeCount":96},[],{"trials":928,"activeCount":96},[],{"trials":930,"activeCount":96},[],{"trials":932,"activeCount":96},[933],{"nctId":934,"briefTitle":935,"status":490,"phases":936,"primaryCompletion":937,"completion":937,"start":938,"enrollment":539,"conditions":939,"interventions":941},"NCT04497831","Morphine for Dyspnea in Pulmonary Fibrosis",[87],"2022-09-21","2020-09-21",[940],"Idiopathic Pulmonary Fibrosis (IPF)",[923],{"trials":943,"activeCount":96},[],{"trials":945,"activeCount":96},[],{"intervention":947,"totalTrials":948,"cells":949},"Losartan",2,{"EARLY_PHASE1":950,"PHASE1":952,"PHASE2":954,"PHASE3":956,"PHASE4":958,"NA":960},{"trials":951,"activeCount":96},[],{"trials":953,"activeCount":96},[],{"trials":955,"activeCount":96},[],{"trials":957,"activeCount":96},[],{"trials":959,"activeCount":96},[],{"trials":961,"activeCount":96},[962,974],{"nctId":963,"briefTitle":964,"status":490,"phases":965,"primaryCompletion":966,"completion":967,"start":968,"enrollment":969,"conditions":970,"interventions":973},"NCT05243446","Cardiorenal Effecs of Losartan in Kidney Transplant Recipients",[],"2022-12-31","2023-12-31","2015-09",740,[971,972],"Renal Transplant Failure","Cardiovascular Complication",[947],{"nctId":975,"briefTitle":976,"status":438,"phases":977,"primaryCompletion":978,"completion":979,"start":980,"enrollment":981,"conditions":982,"interventions":984},"NCT02446548","Influence of Aliskiren on Albuminuria After Kidney Transplantation",[89],"2014-04","2014-11","2013-03",18,[983],"Albuminuria",[985,986],"aliskiren","losartan",{"intervention":988,"totalTrials":92,"cells":989},"Salbutamol 2,5 mg",{"EARLY_PHASE1":990,"PHASE1":992,"PHASE2":994,"PHASE3":996,"PHASE4":998,"NA":1000},{"trials":991,"activeCount":96},[],{"trials":993,"activeCount":96},[],{"trials":995,"activeCount":96},[],{"trials":997,"activeCount":96},[],{"trials":999,"activeCount":96},[],{"trials":1001,"activeCount":96},[1002],{"nctId":1003,"briefTitle":1004,"status":438,"phases":1005,"primaryCompletion":1006,"completion":1007,"start":1008,"enrollment":494,"conditions":1009,"interventions":1012},"NCT01714401","Nebulized Bronchodilators and Cardiac Repolarization",[89],"2013-05-30","2013-12-31","2012-03",[1010,1011],"Influence of Nebulized Bronchodilatators on Selected","Electrophysiological Parameters",[988,1013],"Salbutamol 5mg",{"intervention":1013,"totalTrials":92,"cells":1015},{"EARLY_PHASE1":1016,"PHASE1":1018,"PHASE2":1020,"PHASE3":1022,"PHASE4":1024,"NA":1026},{"trials":1017,"activeCount":96},[],{"trials":1019,"activeCount":96},[],{"trials":1021,"activeCount":96},[],{"trials":1023,"activeCount":96},[],{"trials":1025,"activeCount":96},[],{"trials":1027,"activeCount":96},[1028],{"nctId":1003,"briefTitle":1004,"status":438,"phases":1029,"primaryCompletion":1006,"completion":1007,"start":1008,"enrollment":494,"conditions":1030,"interventions":1031},[89],[1010,1011],[988,1013],{"intervention":1033,"totalTrials":92,"cells":1034},"Administration of 1g tranexamic acid intravenous bolus, after anesthesia was introduced",{"EARLY_PHASE1":1035,"PHASE1":1037,"PHASE2":1039,"PHASE3":1041,"PHASE4":1043,"NA":1045},{"trials":1036,"activeCount":96},[],{"trials":1038,"activeCount":96},[],{"trials":1040,"activeCount":96},[],{"trials":1042,"activeCount":96},[],{"trials":1044,"activeCount":96},[],{"trials":1046,"activeCount":96},[1047],{"nctId":1048,"briefTitle":1049,"status":438,"phases":1050,"primaryCompletion":1051,"completion":1051,"start":1052,"enrollment":1053,"conditions":1054,"interventions":1058},"NCT06038981","Assessment of the Impact of Perioperative Administration of Tranexamic Acid on Bleeding After Sleeve Gastrectomy",[89],"2023-06-28","2022-07-04",300,[1055,1056,1057],"Hemorrhage, Surgical","Bariatric Surgery","Tranexamic Acid",[1033],{"intervention":1060,"totalTrials":92,"cells":1061},"Morphine hydrochloride; Midazolam",{"EARLY_PHASE1":1062,"PHASE1":1064,"PHASE2":1066,"PHASE3":1068,"PHASE4":1070,"NA":1072},{"trials":1063,"activeCount":96},[],{"trials":1065,"activeCount":96},[],{"trials":1067,"activeCount":96},[],{"trials":1069,"activeCount":96},[],{"trials":1071,"activeCount":96},[],{"trials":1073,"activeCount":96},[1074],{"nctId":1075,"briefTitle":1076,"status":438,"phases":1077,"primaryCompletion":1078,"completion":1078,"start":1079,"enrollment":870,"conditions":1080,"interventions":1082},"NCT01066247","Premedication and Haemodynamics After Spinal Anesthesia",[89],"2010-06","2009-09",[1081],"Hemodynamics After Spinal Anesthesia",[1060,1083],"Midazolam",{"intervention":1083,"totalTrials":92,"cells":1085},{"EARLY_PHASE1":1086,"PHASE1":1088,"PHASE2":1090,"PHASE3":1092,"PHASE4":1094,"NA":1096},{"trials":1087,"activeCount":96},[],{"trials":1089,"activeCount":96},[],{"trials":1091,"activeCount":96},[],{"trials":1093,"activeCount":96},[],{"trials":1095,"activeCount":96},[],{"trials":1097,"activeCount":96},[1098],{"nctId":1075,"briefTitle":1076,"status":438,"phases":1099,"primaryCompletion":1078,"completion":1078,"start":1079,"enrollment":870,"conditions":1100,"interventions":1101},[89],[1081],[1060,1083],{"intervention":1103,"totalTrials":92,"cells":1104},"Spironolactone (Spironol) 25 mg",{"EARLY_PHASE1":1105,"PHASE1":1107,"PHASE2":1109,"PHASE3":1111,"PHASE4":1113,"NA":1115},{"trials":1106,"activeCount":96},[],{"trials":1108,"activeCount":96},[],{"trials":1110,"activeCount":96},[],{"trials":1112,"activeCount":96},[],{"trials":1114,"activeCount":96},[],{"trials":1116,"activeCount":96},[1117],{"nctId":1118,"briefTitle":1119,"status":438,"phases":1120,"start":1121,"conditions":1122,"interventions":1123},"NCT00528385","Optimalization of Nephroprotection Using Agents Inhibiting Renin-Angiotensin-Aldosterone System",[89],"2005-03",[15,18],[1103],{"intervention":1125,"totalTrials":92,"cells":1126},"Propofol bolus",{"EARLY_PHASE1":1127,"PHASE1":1129,"PHASE2":1131,"PHASE3":1133,"PHASE4":1135,"NA":1137},{"trials":1128,"activeCount":96},[],{"trials":1130,"activeCount":96},[],{"trials":1132,"activeCount":96},[],{"trials":1134,"activeCount":96},[],{"trials":1136,"activeCount":96},[],{"trials":1138,"activeCount":96},[1139],{"nctId":1140,"briefTitle":1141,"status":438,"phases":1142,"primaryCompletion":1143,"completion":1143,"start":1144,"enrollment":494,"conditions":1145,"interventions":1149},"NCT03917446","Volume Responsiveness Assesment After Propofol.",[],"2020-09-01","2017-09-01",[1146,1147,1148],"Circulatory Failure","Fluid Volume Disorder","Critical Illness",[1125],{"intervention":1151,"totalTrials":92,"cells":1152},"Juvit D3",{"EARLY_PHASE1":1153,"PHASE1":1155,"PHASE2":1157,"PHASE3":1159,"PHASE4":1161,"NA":1163},{"trials":1154,"activeCount":96},[],{"trials":1156,"activeCount":96},[],{"trials":1158,"activeCount":96},[],{"trials":1160,"activeCount":96},[],{"trials":1162,"activeCount":96},[],{"trials":1164,"activeCount":96},[1165],{"nctId":1166,"briefTitle":1167,"status":438,"phases":1168,"primaryCompletion":1169,"completion":1170,"start":1171,"enrollment":494,"conditions":1172,"interventions":1175},"NCT04768023","12 Weeks Vitamin D Supplementation and Physical Activity in PD Patients With DBS",[89],"2020-04-30","2022-02-28","2019-11-01",[1173,1174],"Vitamin D Deficiency","Parkinson Disease",[1151],{"intervention":1177,"totalTrials":92,"cells":1178},"Additional intraoperative analgesia",{"EARLY_PHASE1":1179,"PHASE1":1181,"PHASE2":1183,"PHASE3":1185,"PHASE4":1187,"NA":1189},{"trials":1180,"activeCount":96},[],{"trials":1182,"activeCount":96},[],{"trials":1184,"activeCount":96},[],{"trials":1186,"activeCount":96},[],{"trials":1188,"activeCount":96},[],{"trials":1190,"activeCount":96},[1191],{"nctId":1192,"briefTitle":1193,"status":438,"phases":1194,"primaryCompletion":1195,"completion":1195,"start":1196,"enrollment":286,"conditions":1197,"interventions":1199},"NCT03863899","Analgesia in Patients Undergoing Transfemoral Transcatheter Aortic Valve Implantation (TF-TAVI)",[89],"2019-12-31","2018-07-02",[1198],"Aortic Valve Stenosis",[1177,1200],"Additional postoperative analgesia",{"intervention":1200,"totalTrials":92,"cells":1202},{"EARLY_PHASE1":1203,"PHASE1":1205,"PHASE2":1207,"PHASE3":1209,"PHASE4":1211,"NA":1213},{"trials":1204,"activeCount":96},[],{"trials":1206,"activeCount":96},[],{"trials":1208,"activeCount":96},[],{"trials":1210,"activeCount":96},[],{"trials":1212,"activeCount":96},[],{"trials":1214,"activeCount":96},[1215],{"nctId":1192,"briefTitle":1193,"status":438,"phases":1216,"primaryCompletion":1195,"completion":1195,"start":1196,"enrollment":286,"conditions":1217,"interventions":1218},[89],[1198],[1177,1200],{"intervention":1220,"totalTrials":92,"cells":1221},"Droperidol Injectable Solution",{"EARLY_PHASE1":1222,"PHASE1":1224,"PHASE2":1226,"PHASE3":1228,"PHASE4":1230,"NA":1232},{"trials":1223,"activeCount":96},[],{"trials":1225,"activeCount":96},[],{"trials":1227,"activeCount":96},[],{"trials":1229,"activeCount":96},[],{"trials":1231,"activeCount":96},[],{"trials":1233,"activeCount":96},[1234],{"nctId":1235,"briefTitle":1236,"status":438,"phases":1237,"primaryCompletion":1238,"completion":1238,"start":1239,"enrollment":494,"conditions":1240,"interventions":1242},"NCT03944681","Gender Influence on Torsadogenic Actions of Droperidol.",[89],"2020-12-31","2019-04-23",[1241],"Arrhythmia, Droperidol",[1220],{"intervention":1244,"totalTrials":92,"cells":1245},"Probiotic and vitamin D",{"EARLY_PHASE1":1246,"PHASE1":1248,"PHASE2":1250,"PHASE3":1252,"PHASE4":1254,"NA":1256},{"trials":1247,"activeCount":96},[],{"trials":1249,"activeCount":96},[],{"trials":1251,"activeCount":96},[],{"trials":1253,"activeCount":96},[],{"trials":1255,"activeCount":96},[],{"trials":1257,"activeCount":96},[1258],{"nctId":1259,"briefTitle":1260,"status":490,"phases":1261,"primaryCompletion":1262,"completion":1263,"start":1264,"enrollment":1265,"conditions":1266,"interventions":1269},"NCT04759729","The Effect of Probiotics and Vitamin D Supplementation on Sport Performance in MMA Athletes.",[89],"2021-02-28","2021-03-31","2020-12-01",25,[1267,1268],"Gut Microbiome","Sport Performance",[1244],{"intervention":1271,"totalTrials":92,"cells":1272},"Ketamine",{"EARLY_PHASE1":1273,"PHASE1":1275,"PHASE2":1277,"PHASE3":1279,"PHASE4":1281,"NA":1283},{"trials":1274,"activeCount":96},[],{"trials":1276,"activeCount":96},[],{"trials":1278,"activeCount":96},[],{"trials":1280,"activeCount":96},[],{"trials":1282,"activeCount":96},[],{"trials":1284,"activeCount":96},[1285],{"nctId":1286,"briefTitle":1287,"status":438,"phases":1288,"primaryCompletion":1052,"completion":1052,"start":1289,"enrollment":394,"conditions":1290,"interventions":1293},"NCT04226963","A Naturalistic Study of Ketamine for Treatment Resistant Mood Disorders",[],"2019-12-04",[1291,1292,1271,24],"Treatment Resistant Depression","Bipolar Depression",[1271],{"intervention":1295,"totalTrials":92,"cells":1296},"atorvastatin (Sortis) 40 mg",{"EARLY_PHASE1":1297,"PHASE1":1299,"PHASE2":1301,"PHASE3":1303,"PHASE4":1305,"NA":1307},{"trials":1298,"activeCount":96},[],{"trials":1300,"activeCount":96},[],{"trials":1302,"activeCount":96},[],{"trials":1304,"activeCount":96},[],{"trials":1306,"activeCount":96},[],{"trials":1308,"activeCount":96},[1309],{"nctId":1310,"briefTitle":1311,"status":438,"phases":1312,"start":1313,"conditions":1314,"interventions":1315},"NCT00572312","Optimalization of Nephroprotection Using Atorvastatin (Sortis)",[89],"2005-02",[15,18],[1295],{"intervention":985,"totalTrials":92,"cells":1317},{"EARLY_PHASE1":1318,"PHASE1":1320,"PHASE2":1322,"PHASE3":1324,"PHASE4":1326,"NA":1328},{"trials":1319,"activeCount":96},[],{"trials":1321,"activeCount":96},[],{"trials":1323,"activeCount":96},[],{"trials":1325,"activeCount":96},[],{"trials":1327,"activeCount":96},[],{"trials":1329,"activeCount":96},[1330],{"nctId":975,"briefTitle":976,"status":438,"phases":1331,"primaryCompletion":978,"completion":979,"start":980,"enrollment":981,"conditions":1332,"interventions":1333},[89],[983],[985,986],{"intervention":1335,"totalTrials":92,"cells":1336},"ACC (N-acetylcysteine) 1200 mg",{"EARLY_PHASE1":1337,"PHASE1":1339,"PHASE2":1341,"PHASE3":1343,"PHASE4":1345,"NA":1347},{"trials":1338,"activeCount":96},[],{"trials":1340,"activeCount":96},[],{"trials":1342,"activeCount":96},[],{"trials":1344,"activeCount":96},[],{"trials":1346,"activeCount":96},[],{"trials":1348,"activeCount":96},[1349],{"nctId":1350,"briefTitle":1351,"status":438,"phases":1352,"start":1353,"conditions":1354,"interventions":1355},"NCT00572663","Optimalization of Nephroprotection Using N-Acetylcysteine",[89],"2005-01",[15,18],[1335]]